1. Home
  2. Analysis
  3. Emsam
  4. Profen

Emsam and Profen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Emsam (selegiline) and Profen (ibuprofen). Common drug interactions include nausea among females and hospitalisation among males.

The phase IV clinical study analyzes what interactions people have when they take Emsam and Profen. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.

What is Emsam?

Emsam has active ingredients of selegiline. It is often used in depression. eHealthMe is studying from 1,875 Emsam users. Check the latest studies of Emsam.

What is Profen?

Profen has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 245,311 Profen users. Check the latest studies of Profen.

On Jul, 31, 2026

41 people who take Emsam and Profen together, and have interactions are studied.

Emsam and Profen drug interactions.

What are the common drug interactions of Emsam and Profen, by gender? *:

female:

  1. Nausea (feeling of having an urge to vomit)
  2. Headache (pain in head)
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Confusional state
  5. Dysarthria (speech disorder)
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Application site erythema (redness of the skin at application site)
  8. Insomnia (sleeplessness)
  9. Dizziness
  10. Influenza like illness

male:

  1. Hospitalisation
  2. Schizophrenia (a mental disorder characterized by a breakdown of thought processes)
  3. Therapeutic response unexpected
  4. Weight increased
  5. Application site discolouration
  6. Application site erythema (redness of the skin at application site)
  7. Application site mass
  8. Application site pruritus (application site severe itching of the skin)
  9. Diarrhoea
  10. Headache (pain in head)

What are the common drug interactions of Emsam and Profen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Headache (pain in head)
  2. Insomnia (sleeplessness)
  3. Lumbar puncture

20-29:

  1. Chest pain
  2. Dyspnoea (difficult or laboured respiration)
  3. Emotional distress
  4. Injury
  5. Pulmonary embolism (blockage of the main artery of the lung)
  6. Diarrhoea
  7. Insomnia (sleeplessness)

30-39:

  1. Ankle fracture
  2. Confusional state
  3. Encephalopathy (functioning of the brain is affected by some agent or condition)
  4. Gout (uric acid crystals building up in the body)
  5. Lung disorder (lung disease)
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Therapeutic response unexpected
  8. Anxiety
  9. Blood pressure decreased
  10. Dizziness

40-49:

  1. Nausea (feeling of having an urge to vomit)
  2. Dizziness
  3. Application site discomfort
  4. Application site erythema (redness of the skin at application site)
  5. Application site pruritus (application site severe itching of the skin)
  6. Application site rash
  7. Application site urticaria
  8. Abdominal discomfort
  9. Blood pressure increased
  10. Change of bowel habit

50-59:

  1. Pancreatitis acute (sudden inflammation of pancreas)
  2. Pathogen resistance
  3. Affect lability (emotional incontinence)
  4. Aggression
  5. Alanine aminotransferase increased
  6. Anger
  7. Aspartate aminotransferase increased
  8. Blood bilirubin increased
  9. Headache (pain in head)
  10. Suicidal ideation

60+:

  1. Confusional state
  2. Dysarthria (speech disorder)
  3. Retinal oedema (swelling of retina)
  4. Vision blurred
  5. Somnolence (a state of near-sleep, a strong desire for sleep)
  6. Influenza like illness
  7. Abdominal pain
  8. Depressed mood
  9. Drug effect decreased
  10. Insomnia (sleeplessness)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 13 people, 31.71%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 11 people, 26.83%
  3. Toothaches (tooth pain): 8 people, 19.51%
  4. Stiff Person Syndrome: 6 people, 14.63%
  5. Immunodeficiency Common Variable: 6 people, 14.63%
  6. Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 5 people, 12.20%
  7. Birth Control: 3 people, 7.32%

* Approximation only. Some reports may have incomplete information.

Do you take Emsam and Profen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Emsam and Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Emsam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Emsam and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Profen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on selegiline and ibuprofen (the active ingredients of Emsam and Profen, respectively), and Emsam and Profen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.